

WOLVERHAMPTON CCG

Governing Body
12 February 2019

Agenda item 12

TITLE OF REPORT:	Commissioning Committee – January 2019
AUTHOR(s) OF REPORT:	Dr Manjit Kainth
MANAGEMENT LEAD:	Mr Steven Marshall
PURPOSE OF REPORT:	To provide the Governing Body of Wolverhampton Clinical Commissioning Group (CCG) with an update from the Commissioning Committee in January 2019
ACTION REQUIRED:	<input type="checkbox"/> Decision <input checked="" type="checkbox"/> Assurance
PUBLIC OR PRIVATE:	This Report is intended for the public domain.
KEY POINTS:	This report is submitted to meet the Committee's constitutional requirement to provide a written summary of the matters considered at each meeting and to escalate any significant issues that need to be brought to the attention of the Governing Body.
RECOMMENDATION:	That the report is noted.
LINK TO BOARD ASSURANCE FRAMEWORK AIMS & OBJECTIVES:	[Outline how the report is relevant to the Strategic Aims and objectives in the Board Assurance Framework – See Notes for Further information]
1. Improving the quality and safety of the services we commission	
2. Reducing Health Inequalities in Wolverhampton	
3. System effectiveness delivered within our financial envelope	



1. BACKGROUND AND CURRENT SITUATION

- 1.1 The purpose of the report is to provide an update from Commissioning Committee to the Governing Body of Wolverhampton Clinical Commissioning Group (CCG) from the January 2019 meeting.

2. MAIN BODY OF REPORT

2.1 Diagnostic Pathway for Autistic Spectrum

The Committee was presented with a report of an all age strategy developed by Wolverhampton CCG working collaterally with the City Council towards a clear pathway across the system. This will include further conditions such as ASD and ADHD and will ensure the quality and safety of the service.

The Committee noted the above and assurance was given

Action - That Governing Body notes the decision made by the Committee

2.2 Glaucoma Referral Refinement Service

The Committee was presented with a report to ensure safety and performance continuation with a change to the pathway for a small number of patients with suspected glaucoma; activity and financial input are minimal as the infrastructure is in place to enable this change.

The Committee noted the above and approval was given.

Action - That Governing Body notes the decision made by the Committee

2.3 Contracting Update Report

Royal Wolverhampton NHS Trust

Activity/ Performance

The Committee was updated with the current performance of Cancer, whereby the trust continues to perform below the required contract standard. Updates were also given in relation to Referral to Treatment waiting times, A&E 4 hour target, Ambulance handover and Diagnostics.

Activity Queries

Following on from the November 2018 report, queries remain outstanding for Phlebotomy and Community Children's Nursing services; both of which are subject to ongoing investigation by RWT.

2019/20 Planning Round

Good progress is being made via the three sub-groups. The next phase of work relates to interpretation of national planning guidance and incorporation of the requirements into an initial offer.

Dermatology

Work continues on a project to re-procure community dermatology services which involves movement of some activity out of RWT. A second joint meeting is due to take place with the trust in February.

Black Country Partnership Foundation Trust (BCPFT)

Performance/ Quality Issues

Improving access to Psychological Therapies (IAPT) Targets

The CCG is investing additional funding in the IAPT service at BCPFT to help ensure delivery of the Recovery target. The trust is currently in the process of recruiting additional staff and sourcing training, and we are awaiting feedback on where they are in the plan and their current position.

WMAS – Non-Emergency Patient Transport Service (NEPTS)

The CCG has received a Contract Extension Proposal from WMAS which requests a significant increase in funding. Further detail is awaited from WMAS to validate their figure. A specific paper will be taken to the private Governing Body meeting in February to provide an update and outline the CCG's options.

Business Cases Panel

Extension of Biologics in Rheumatoid Arthritis (RA)

A business case was received from RWT for the extension of current NICE pathway for Biologics in Rheumatoid Arthritis. The business case asks for approval to allow 4th and 5th line therapy thus preventing treatment delays and avoiding the need for Individual Funding Requests. The committee approved the business case.

Action - The Governing Body notes the updates provided and the support for the RA Biologics business case.

2.2 Medicines Optimisation Strategy

The Committee was presented with a Strategy to delivery corporate objectives across the CCG and STP. It outlines how the plan to achieve medicines management optimisation to deliver a safety and value.

Key deliverables include –

- Patient ordering of repeat prescriptions
- Care homes
- Reviews
- Effects on the local health economy
- High cost drug validation
- Delivering of the QIPP programme

The Committee noted the above and approval was given

Action - That Governing Body notes the decision made by the Committee

2.2 Review of Risks

The committee received an update of the risk register highlighting the current risks.

Action - That Governing Body notes the update provided.

3. RECOMMENDATIONS

- Receive and discuss the report.
- Note the action being taken.

Name: Dr Manjit Kainth

Job Title: Lead for Commissioning & Contracting

Date: 31st January 2019

